FDA says Novartis' Prexige 'not approvable'

Share this article:

Novartis said it has received a "not approvable" letter from the FDA for its COX-2 inhibitor Prexige (lumiracoxib) as an arthritis treatment.

The drugmaker said plans to continue discussions with FDA and believes Prexige  is “a valuable treatment option for appropriate patients with osteoarthritic pain.”

Novartis had touted Prexige as a potential blockbuster, with hopes for sales of over $1 billion a year, but CEO Daniel Vasella said earlier this month that the drug was a long shot to gain US approval after Australian regulators decided to withdraw it from the market in early 2007 due to safety concerns.

Recent setbacks for Novartis mean the company doesn't expect to return to double-digit sales growth until the second half of 2008, Vasella told investors last month.

“We had a significant number of disappointments,” Vasella said in a published report. We “will have a much less dynamic year in the pharma business in the second half (than in the first), which will affect the group as a whole.”

Share this article:
You must be a registered member of MMM to post a comment.

Next Article in Channel


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...